Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0056 in Adult Healthy Subjects
NCT06612970Phase 1Completed
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB0056 (8 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Percentage of subjects with drug related adverse events up to 2700 hours. Started Nov 2024; status: completed.
02
Drugs
HB0056
Beyond the preview
Go deeper on NCT06612970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612970.